Symbols

MTVA

MetaVia·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MTVA

Metavia Inc.

A biotechnology company dedicated to developing drugs for the treatment of cardiovascular metabolic diseases

Industry

Pharmaceutical

Established Date

Listing Date

08/05/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.metaviatx.com

Security Type

Common stock

Office address

545 Concord Avenue Suite 210 Cambridge Massachusetts 02138

Business

Introduction

MetaVia Inc., was incorporated in October 2014 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on the development of novel drugs for the treatment of cardiovascular and metabolic diseases, with major projects targeting metabolic dysfunction-related steatohepatitis and obesity. Its R&D pipeline includes GPR119 agonist vanoglipel and oxyntomodulin analog dual agonist DA-1726.

Company Financials

EPS

MTVA has released its 2025 Q4 earnings. EPS was reported at 1.01, versus the expected -1.82, beating expectations. The chart below visualizes how MTVA has performed over recent quarters, highlighting trends in earnings surprises.